

David Viñal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7135829/publications.pdf>

Version: 2024-02-01

17
papers

150
citations

1162367

8
h-index

1199166

12
g-index

20
all docs

20
docs citations

20
times ranked

215
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence of venous thromboembolic events in cancer patients receiving immunotherapy: a single-institution experience. <i>Clinical and Translational Oncology</i> , 2021, 23, 1245-1252.	1.2	21
2	Genomic profiling in non-small-cell lung cancer in young patients. A systematic review. <i>ESMO Open</i> , 2021, 6, 100045.	2.0	18
3	Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review. <i>ESMO Open</i> , 2021, 6, 100223.	2.0	18
4	Gp-100 as a Novel Therapeutic Target in Uveal Melanoma. <i>Cancers</i> , 2021, 13, 5968.	1.7	16
5	Prognostic value of neutrophil-to-lymphocyte ratio and other inflammatory markers in patients with high-risk soft tissue sarcomas. <i>Clinical and Translational Oncology</i> , 2020, 22, 1849-1856.	1.2	12
6	Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy. <i>Clinical and Translational Oncology</i> , 2021, 23, 1185-1192.	1.2	12
7	Epidemiology and natural history of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa patients: 20 years' experience of a reference centre in Spain. <i>Clinical and Translational Oncology</i> , 2019, 21, 1573-1577.	1.2	11
8	Efficacy of rechallenge with BRAF inhibition therapy in patients with advanced BRAFV600 mutant melanoma. <i>Clinical and Translational Oncology</i> , 2019, 21, 1061-1066.	1.2	11
9	Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital. <i>JCO Clinical Cancer Informatics</i> , 2022, , .	1.0	7
10	Efficacy of capecitabine when used concomitantly with proton pump inhibitors in cancer patients: a systematic review. <i>Clinical and Translational Oncology</i> , 2020, 22, 1288-1294.	1.2	5
11	Genomic profiling in oncology clinical practice. <i>Clinical and Translational Oncology</i> , 2020, 22, 1430-1439.	1.2	4
12	Yttrium-90 transarterial radioembolization in patients with gastrointestinal malignancies. <i>Clinical and Translational Oncology</i> , 2022, 24, 796-808.	1.2	4
13	In-depth proteomics characterization of ^{67}Zn effectors identifies key proteins with diagnostic potential implicated in lymphangiogenesis, vasculogenesis and metastasis in colorectal cancer. <i>Molecular Oncology</i> , 2022, 16, 2672-2692.	2.1	4
14	^{67}Zn , TAp73 and ^{133}P 53 Extracellular Vesicle Cargo as Early Diagnosis Markers in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 2240.	1.7	3
15	Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience. <i>Clinical and Translational Oncology</i> , 2021, 23, 1838-1846.	1.2	1
16	Clinicopathological characteristics and outcomes of patients with deficient mismatch repair colorectal cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 181-181.	0.8	1
17	Radium 223 for the treatment of metastatic castration-resistant prostate cancer. <i>Archivos Espanoles De Urologia</i> , 2019, 72, 500-507.	0.1	1